US equities |
MU $1,087.67 ▲+4.03% NVDA $236.94 ▼-0.96% SNDK $1,726.96 ▲+4.00% SPCX $167.94 ▼-2.31% AMD $646.26 ▼-0.49% INTC $112.88 ▲+0.34% TSLA $376.70 ▼-1.05% AAPL $336.75 ▲+0.94%
FinancialContent

INmune Bio Inc. - Common stock (NQ:INMB)

1.875 +0.005 (+0.27%)
Delayed Quote Updated: 2:32 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
C-Suite Buy of the Week: Executive Moves from Biotech to Banking ↗
 
Via Benzinga
News headline image
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From OmniScience
Via Business Wire
News headline image
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces $13.0 Million Registered Direct Offering
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INmune Bio Inc. to Join Russell 3000® Index
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INMB Stock Earnings: INmune Bio Misses EPS, Misses Revenue for Q1 2024 ↗
INMB stock results show that INmune Bio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >